Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Diagnostic yield of targeted next generation sequencing in 2002 Dutch cardiomyopathy patients.

Authors:
Mohamed Z Alimohamed Lennart F Johansson Anna Posafalvi Ludolf G Boven Krista K van Dijk Lisa Walters Yvonne J Vos Helga Westers Yvonne M Hoedemaekers Richard J Sinke Rolf H Sijmons Birgit Sikkema-Raddatz Jan D H Jongbloed Paul A van der Zwaag

Int J Cardiol 2021 Mar 1. Epub 2021 Mar 1.

University of Groningen, University Medical Center Groningen, Department of Genetics, Hanzeplein 1, 9713 GZ Groningen, the Netherlands.

Background: Next-generation sequencing (NGS) is increasingly used for clinical evaluation of cardiomyopathy patients as it allows for simultaneous screening of multiple cardiomyopathy-associated genes. Adding copy number variant (CNV) analysis of NGS data is not routine yet and may contribute to the diagnostic yield.

Objectives: Determine the diagnostic yield of our targeted NGS gene panel in routine clinical diagnostics of Dutch cardiomyopathy patients and explore the impact of exon CNVs on diagnostic yield.

Methods: Patients (N = 2002) referred for clinical genetic analysis underwent diagnostic testing of 55-61 genes associated with cardiomyopathies. Samples were analyzed and evaluated for single nucleotide variants (SNVs), indels and CNVs. CNVs identified in the NGS data and suspected of being pathogenic based on type, size and location were confirmed by additional molecular tests.

Results: A (likely) pathogenic (L)P variant was detected in 22.7% of patients, including 3 with CNVs and 25 where a variant was identified in a gene currently not associated with the patient's cardiomyopathy subtype. Only 15 out of 2002 patients (0.8%) were found to carry two (L)P variants.

Conclusion: The yield of routine clinical diagnostics of cardiomyopathies was relatively low when compared to literature. This is likely due to the fact that our study reports the outcome of patients in daily routine diagnostics, therefore also including patients not fully fulfilling (subtype specific) cardiomyopathy criteria. This may also explain why (L)P variants were identified in genes not associated with the reported subtype. The added value of CNV analysis was shown to be limited but not negligible.

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ijcard.2021.02.069DOI Listing
March 2021

Publication Analysis

Top Keywords

cardiomyopathy patients
12
dutch cardiomyopathy
8
genes associated
8
clinical diagnostics
8
routine clinical
8
ngs data
8
patients
8
cnv analysis
8
yield targeted
8
diagnostic yield
8
cardiomyopathy
5
diagnostic
5
type size
4
including cnvs
4
size location
4
227% patients
4
based type
4
suspected pathogenic
4
pathogenic based
4
location confirmed
4

Keyword Occurance

Similar Publications

Cardiovascular toxicity of breast cancer treatment: an update.

Authors:
Christos Papageorgiou Angeliki Andrikopoulou Meletios-Athanasios Dimopoulos Flora Zagouri

Cancer Chemother Pharmacol 2021 Apr 17. Epub 2021 Apr 17.

Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 80 Vasilissis Sofias Avenue, 11528, Athens, Greece.

Novel chemotherapeutic agents have marked a new era in oncology during the past decade, prolonging significantly the overall survival of breast cancer patients. Nevertheless, contemporary antineoplastic treatments can frequently cause adverse cardiovascular side effects. Common manifestations of chemotherapy-induced cardiotoxicity include cardiomyopathy, ischemia, conduction disturbances, hypertension and thromboembolic events, while the type of the treatment regimen administered crucially determines clinical outcome. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Accuracy of health-related quality of life in identifying systolic dysfunction in patients with Chagas cardiomyopathy.

Authors:
Matheus Ribeiro Ávila Pedro Henrique Scheidt Figueiredo Vanessa Pereira Lima Whesley Tanor Silva Marcus Vinícius Accetta Vianna Laís Helena Carvalho Fernandes Alda Cristina Alves de Azevedo Márcia Maria Oliveira Lima Alessandra de Carvalho Bastone Maria do Carmo Pereira Nunes Mauro Felippe Felix Mediano Manoel Otávio da Costa Rocha Henrique Silveira Costa

Trop Med Int Health 2021 Apr 17. Epub 2021 Apr 17.

Physical Therapy School, Healthy and Biological Sciences Faculty, Universidade Federal dos Vales do Jequitinhonha e Mucuri, Diamantina, Brazil.

Objective: Systolic dysfunction is a well-established marker of mortality in patients with Chagas cardiomyopathy (CC). However, its diagnosis is expensive and useful tools for screening these patients are required. The evaluation of the health-related quality of life (HRQoL) detects the patient's perception of the disease's impact. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Diagnosis and treatment of HCV heart diseases.

Authors:
Mohammad Haykal Akira Matsumori Ahmed Saleh Moatez Fayez Hany Negm Mohammad Shalaby Samar Bassuony

Expert Rev Cardiovasc Ther 2021 Apr 16. Epub 2021 Apr 16.

Cardiovascular and ultrasonography research unit (CURU); Research Institute of Ophthalmology (RIO).

Introduction: Hepatitis C virus (HCV) infection is an important cause of a variety of otherwise unexplained heart diseases and myocardial injury. A high prevalence of HCV infection has been noted in patients with hypertrophic cardiomyopathy, dilated cardiomyopathy, arrhythmogenic right ventricular dysplasia/cardiomyopathy and myocarditis. Various arrhythmias, conduction disturbances and QT prolongation were also associated with HCV infection. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

[Dilated cardiomyopathy in children].

Authors:
Gonzalo Urcelay

Rev Chil Pediatr 2020 Dec 8;91(6):860-866. Epub 2020 Oct 8.

Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Pediatric cardiomyopathies are infrequent diseases of the cardiac muscle, with an annual inciden ce of 1.1 to 1.2 per 100,000 children. Read More

View Article and Full-Text PDF
December 2020
Similar Publications

Hypertrophic cardiomyopathy considerations for the managed care pharmacist.

Authors:
Patty Taddei-Allen

Am J Manag Care 2021 Apr;27(6 Suppl):S118-S125

Vice President, Clinical Programs and Services, WellDyne, Lakeland, FL. Email:

Hypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and with some patients, there is no evidence of a genetic etiology or presence of HCM in family members. Young age at diagnosis and the presence of a pathogenic or likely pathogenic sarcomere variant predict greater lifelong risk for stroke, heart failure, ventricular arrhythmia, atrial fibrillation, or mortality. Read More

View Article and Full-Text PDF
April 2021
Similar Publications